Yingxue Ren
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yingxue Ren has a total of 116 co-authors. Here are the top co-authors by number of shared publications:
- Guojun Bu
Department of Neuroscience, Mayo Clinic, Jacksonville, USA
3 shared publications - Xianlin Han
Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, San Antonio, USA
3 shared publications - Chia-Chen Liu
Department of Neuroscience, Mayo Clinic, Jacksonville, USA
2 shared publications - David M. Holtzman
Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer’s Disease Research Center, Washington University in St. Louis, St. Louis, USA
2 shared publications - Dennis W. Dickson
Department of Neuroscience, Mayo Clinic, Jacksonville, USA
2 shared publications - Fuyao Li
Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA
2 shared publications
Latest Publications
- Open Access
- 8 October 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
APOE2 attenuates APOE4-associated amyloid pathology and related toxicity in a mouse model of Alzheimer’s disease
The apolipoprotein E ( APOE ) gene is the strongest genetic risk factor for Alzheimer’s disease (AD), influencing amyloid-β (Aβ) aggregation, clearance, and glial function. While APOE4 promotes Aβ pathology and APOE2 is protective, how these opposing alleles interact in the heterozygous APOE2/4 state remains unknown. Here, using littermate-controlled heterozygous APOE mice ( APOE2/3 , APOE3/4 , and APOE2/4 ) alongside APOE3/3 controls crossed with 5xFAD mice, we show that APOE3/4 mice exhibit increased Aβ deposition, maladaptive microglial activation, and reduced microglial interactions with plaques. These changes were attenuated in APOE2/4 mice, accompanied by a brain proteomic profile more similar to those of APOE3/3 and APOE2/3 mice. Increased myelin basic protein (MBP) abundance was observed in APOE2/3 but not APOE2/4 mice. Plasma lipidomics revealed shared alterations in APOE3/4 and APOE2/4 mice, with distinct signatures in APOE2/3 mice. These findings define allele interaction-dependent effects of APOE on brain and systemic phenotypes and provide a framework for understanding the biological consequences of the APOE2/4 genotype.
- 8 October 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessAPOE2 attenuates APOE4-associated amyloid pathology and related toxicity in a mouse model of Alzheimer’s disease
The apolipoprotein E ( APOE ) gene is the strongest genetic risk factor for Alzheimer’s disease (AD), influencing amyloid-β (Aβ) aggregation, clearance, and glial function. While APOE4 promotes Aβ pathology and APOE2 is protective, how these opposing alleles interact in the heterozygous APOE2/4 state remains unknown. Here, using littermate-controlled heterozygous APOE mice ( APOE2/3 , APOE3/4 , and APOE2/4 ) alongside APOE3/3 controls crossed with 5xFAD mice, we show that APOE3/4 mice exhibit increased Aβ deposition, maladaptive microglial activation, and reduced microglial interactions with plaques. These changes were attenuated in APOE2/4 mice, accompanied by a brain proteomic profile more similar to those of APOE3/3 and APOE2/3 mice. Increased myelin basic protein (MBP) abundance was observed in APOE2/3 but not APOE2/4 mice. Plasma lipidomics revealed shared alterations in APOE3/4 and APOE2/4 mice, with distinct signatures in APOE2/3 mice. These findings define allele interaction-dependent effects of APOE on brain and systemic phenotypes and provide a framework for understanding the biological consequences of the APOE2/4 genotype.
- Open Access
- 28 September 2026
- Published by Oxford University Press (OUP) in NAR Genomics and Bioinformatics
- Vol. 8 (4)
scMINA: an interpretable workflow for paired scRNA–scATAC multiome integration and regulatory prioritization
Single-cell multiomic technologies that jointly profile transcriptomic and epigenomic states provide unprecedented opportunities to investigate cellular heterogeneity and gene regulatory mechanisms in complex diseases. However, analysis of paired single-cell RNA-seq (scRNA-seq) and chromatin accessibility (scATAC-seq) data remains computationally challenging due to modality-specific technical variation, integration complexity, and limited interpretability of downstream regulatory inference. Here, we present scMINA (single-cell Multimodal Integration and Network Attribution), a modular and interpretable analytical workflow for the analysis of paired single-cell multiome datasets. scMINA comprises coordinated modules for multimodal integration, technical covariate correction, and regulatory feature prioritization, enabling systematic characterization of cellular states across transcriptomic and epigenomic modalities. In addition, scMINA incorporates explainable artificial intelligence-based attribution strategies to prioritize candidate genes and transcription factors associated with cell-state heterogeneity and disease-related regulatory alterations. We applied scMINA to the single-cell multiome data from the Seattle Alzheimer’s Disease Brain Cell Atlas, where the workflow robustly resolved major glial cell populations and identified regulatory features associated with Alzheimer’s disease pathology. By coupling multimodal integration with interpretable regulatory prioritization, scMINA provides a practical workflow for systematic analysis and biological interpretation of paired scRNA-seq and scATAC-seq datasets.
- 28 September 2026
- Published by Oxford University Press (OUP) in NAR Genomics and Bioinformatics
- Vol. 8 (4)
Open AccessscMINA: an interpretable workflow for paired scRNA–scATAC multiome integration and regulatory prioritization
Single-cell multiomic technologies that jointly profile transcriptomic and epigenomic states provide unprecedented opportunities to investigate cellular heterogeneity and gene regulatory mechanisms in complex diseases. However, analysis of paired single-cell RNA-seq (scRNA-seq) and chromatin accessibility (scATAC-seq) data remains computationally challenging due to modality-specific technical variation, integration complexity, and limited interpretability of downstream regulatory inference. Here, we present scMINA (single-cell Multimodal Integration and Network Attribution), a modular and interpretable analytical workflow for the analysis of paired single-cell multiome datasets. scMINA comprises coordinated modules for multimodal integration, technical covariate correction, and regulatory feature prioritization, enabling systematic characterization of cellular states across transcriptomic and epigenomic modalities. In addition, scMINA incorporates explainable artificial intelligence-based attribution strategies to prioritize candidate genes and transcription factors associated with cell-state heterogeneity and disease-related regulatory alterations. We applied scMINA to the single-cell multiome data from the Seattle Alzheimer’s Disease Brain Cell Atlas, where the workflow robustly resolved major glial cell populations and identified regulatory features associated with Alzheimer’s disease pathology. By coupling multimodal integration with interpretable regulatory prioritization, scMINA provides a practical workflow for systematic analysis and biological interpretation of paired scRNA-seq and scATAC-seq datasets.
- Top Cited PapersOpen Access
- 14 February 2026
- Published by Elsevier in Journal of Lipid Research
- Vol. 67 (3) , 101000
Lipidome and proteome of astrocyte and microglia ApoE lipoprotein reveal differences based on cell type and ApoE isoform
- 14 February 2026
- Published by Elsevier in Journal of Lipid Research
- Vol. 67 (3) , 101000
Top Cited PapersOpen AccessLipidome and proteome of astrocyte and microglia ApoE lipoprotein reveal differences based on cell type and ApoE isoform
- Open Access
- 4 February 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
A split biotin ligase approach reveals proteins associated with oligomeric alpha-synuclein during aggregation
Lewy pathology can form over decades in patients with Lewy body diseases, but the causal cellular mechanisms associated with this process remain unclear. This project aims to discover proteins that associate with monomeric and/or oligomeric alpha-synuclein during early stages of the aggregation process. To mimic aggregation processes, cells expressing a synuclein-biotin ligase fusion protein were treated with human recombinant pre-formed fibrils and subjected to BioSITe and mass spectrometry. Using a novel split biotin ligase fused to alpha-synuclein facilitated the identification of proteins specifically associated with multimeric alpha-synuclein. A total of 581 proteins were differentiated into potential interactors of monomeric versus multimeric alpha-synuclein in physiological versus aggregated conditions. The data reveal potentially relevant phosphorylation mechanisms, connections to insulin processing, and a potential interaction with ALS/FTD-associated FUS. Interestingly, we propose that loss of specific interactions may contribute to pathology in patients with sporadic onset of Lewy body diseases. Future studies will validate both true interaction of highlighted proteins with alpha-synuclein, and the impact of such proteins on alpha-synuclein aggregation.
- 4 February 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessA split biotin ligase approach reveals proteins associated with oligomeric alpha-synuclein during aggregation
Lewy pathology can form over decades in patients with Lewy body diseases, but the causal cellular mechanisms associated with this process remain unclear. This project aims to discover proteins that associate with monomeric and/or oligomeric alpha-synuclein during early stages of the aggregation process. To mimic aggregation processes, cells expressing a synuclein-biotin ligase fusion protein were treated with human recombinant pre-formed fibrils and subjected to BioSITe and mass spectrometry. Using a novel split biotin ligase fused to alpha-synuclein facilitated the identification of proteins specifically associated with multimeric alpha-synuclein. A total of 581 proteins were differentiated into potential interactors of monomeric versus multimeric alpha-synuclein in physiological versus aggregated conditions. The data reveal potentially relevant phosphorylation mechanisms, connections to insulin processing, and a potential interaction with ALS/FTD-associated FUS. Interestingly, we propose that loss of specific interactions may contribute to pathology in patients with sporadic onset of Lewy body diseases. Future studies will validate both true interaction of highlighted proteins with alpha-synuclein, and the impact of such proteins on alpha-synuclein aggregation.
- Open Access
- 30 May 2025
- Published by Oxford University Press (OUP) in Bioinformatics
- Vol. 41 (6)
DiSC: a statistical tool for fast differential expression analysis of individual-level single-cell RNA-seq data
Motivation: Single-cell RNA sequencing (scRNA-seq) has become an important method for characterizing cellular heterogeneity, revealing more biological insights than the bulk RNA-seq. The surge in scRNA-seq data across multiple individuals calls for efficient and statistically powerful methods for differential expression (DE) analysis that addresses individual-level biological variability. Results: We introduced DiSC, a method for conducting individual-level DE analysis by extracting multiple distributional characteristics, jointly testing their association with a variable of interest, and using a flexible permutation testing framework to control the false discovery rate (FDR). Our simulation studies demonstrated that DiSC effectively controlled the FDR across various settings and exhibited high statistical power in detecting different types of gene expression changes. Moreover, DiSC is computationally efficient and scalable to the rapidly increasing sample sizes in scRNA-seq studies. When applying DiSC to identify DE genes potentially associated with COVID-19 severity and Alzheimer’s disease across various types of peripheral blood mononuclear cells and neural cells, we found that our method was approximately 100 times faster than other state-of-the-art methods and the results were consistent and supported by existing literature. While DiSC was developed for scRNA-seq data, its robust testing framework can also be applied to other types of single-cell data. We applied DiSC to cytometry by time-of-flight data, DiSC identified significantly more DE markers than traditional methods. Availability and implementation: The R software package “SingleCellStat” is freely available on CRAN (https://cran.r-project.org/web/packages/SingleCellStat/index.html) and GitHub (https://github.com/Lujun995/DiSC). The replication code for reproducing the analyses in this study is publicly accessible at https://github.com/Lujun995/DiSC_Replication_Code. The scRNA-seq expression matrix and metadata utilized in our simulations and analyses can be retrieved from https://cells.ucsc.edu/autism/rawMatrix.zip, https://cellxgene.cziscience.com/collections/1ca90a2d-2943-483d-b678-b809bf464c30, and https://covid19.cog.sanger.ac.uk/submissions/release1/haniffa21.processed.h5ad.
- 30 May 2025
- Published by Oxford University Press (OUP) in Bioinformatics
- Vol. 41 (6)
Open AccessDiSC: a statistical tool for fast differential expression analysis of individual-level single-cell RNA-seq data
Motivation: Single-cell RNA sequencing (scRNA-seq) has become an important method for characterizing cellular heterogeneity, revealing more biological insights than the bulk RNA-seq. The surge in scRNA-seq data across multiple individuals calls for efficient and statistically powerful methods for differential expression (DE) analysis that addresses individual-level biological variability. Results: We introduced DiSC, a method for conducting individual-level DE analysis by extracting multiple distributional characteristics, jointly testing their association with a variable of interest, and using a flexible permutation testing framework to control the false discovery rate (FDR). Our simulation studies demonstrated that DiSC effectively controlled the FDR across various settings and exhibited high statistical power in detecting different types of gene expression changes. Moreover, DiSC is computationally efficient and scalable to the rapidly increasing sample sizes in scRNA-seq studies. When applying DiSC to identify DE genes potentially associated with COVID-19 severity and Alzheimer’s disease across various types of peripheral blood mononuclear cells and neural cells, we found that our method was approximately 100 times faster than other state-of-the-art methods and the results were consistent and supported by existing literature. While DiSC was developed for scRNA-seq data, its robust testing framework can also be applied to other types of single-cell data. We applied DiSC to cytometry by time-of-flight data, DiSC identified significantly more DE markers than traditional methods. Availability and implementation: The R software package “SingleCellStat” is freely available on CRAN (https://cran.r-project.org/web/packages/SingleCellStat/index.html) and GitHub (https://github.com/Lujun995/DiSC). The replication code for reproducing the analyses in this study is publicly accessible at https://github.com/Lujun995/DiSC_Replication_Code. The scRNA-seq expression matrix and metadata utilized in our simulations and analyses can be retrieved from https://cells.ucsc.edu/autism/rawMatrix.zip, https://cellxgene.cziscience.com/collections/1ca90a2d-2943-483d-b678-b809bf464c30, and https://covid19.cog.sanger.ac.uk/submissions/release1/haniffa21.processed.h5ad.
- Open Access
- 15 September 2022
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 219 (12)
Elevating microglia TREM2 reduces amyloid seeding and suppresses disease-associated microglia
TREM2 is exclusively expressed by microglia in the brain and is strongly linked to the risk for Alzheimer’s disease (AD). As microglial responses modulated by TREM2 are central to AD pathogenesis, enhancing TREM2 signaling has been explored as an AD therapeutic strategy. However, the effective therapeutic window targeting TREM2 is unclear. Here, by using microglia-specific inducible mouse models overexpressing human wild-type TREM2 (TREM2-WT) or R47H risk variant (TREM2-R47H), we show that TREM2-WT expression reduces amyloid deposition and neuritic dystrophy only during the early amyloid seeding stage, whereas TREM2-R47H exacerbates amyloid burden during the middle amyloid rapid growth stage. Single-cell RNA sequencing reveals suppressed disease-associated microglia (DAM) signature and reduced DAM population upon TREM2-WT expression in the early stage, whereas upregulated antigen presentation pathway is detected with TREM2-R47H expression in the middle stage. Together, our findings highlight the dynamic effects of TREM2 in modulating AD pathogenesis and emphasize the beneficial effect of enhancing TREM2 function in the early stage of AD development.
- 15 September 2022
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 219 (12)
Open AccessElevating microglia TREM2 reduces amyloid seeding and suppresses disease-associated microglia
TREM2 is exclusively expressed by microglia in the brain and is strongly linked to the risk for Alzheimer’s disease (AD). As microglial responses modulated by TREM2 are central to AD pathogenesis, enhancing TREM2 signaling has been explored as an AD therapeutic strategy. However, the effective therapeutic window targeting TREM2 is unclear. Here, by using microglia-specific inducible mouse models overexpressing human wild-type TREM2 (TREM2-WT) or R47H risk variant (TREM2-R47H), we show that TREM2-WT expression reduces amyloid deposition and neuritic dystrophy only during the early amyloid seeding stage, whereas TREM2-R47H exacerbates amyloid burden during the middle amyloid rapid growth stage. Single-cell RNA sequencing reveals suppressed disease-associated microglia (DAM) signature and reduced DAM population upon TREM2-WT expression in the early stage, whereas upregulated antigen presentation pathway is detected with TREM2-R47H expression in the middle stage. Together, our findings highlight the dynamic effects of TREM2 in modulating AD pathogenesis and emphasize the beneficial effect of enhancing TREM2 function in the early stage of AD development.
- Open Access
- 1 November 2021
- Published by Springer Nature in Acta Neuropathologica
- Vol. 143 (1) , 119-121
Correction to: Apolipoprotein E regulates lipid metabolism and α‑synuclein pathology in human iPSC‑derived cerebral organoids
- 1 November 2021
- Published by Springer Nature in Acta Neuropathologica
- Vol. 143 (1) , 119-121
Open AccessCorrection to: Apolipoprotein E regulates lipid metabolism and α‑synuclein pathology in human iPSC‑derived cerebral organoids
- 1 April 2021
- Published by Elsevier in Neuroscience Letters
- Vol. 749, 135723
Investigating ELOVL7 coding variants in multiple system atrophy
- 1 April 2021
- Published by Elsevier in Neuroscience Letters
- Vol. 749, 135723
Investigating ELOVL7 coding variants in multiple system atrophy
- Open Access
- 1 October 2020
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 8 (Suppl 2) , A8
P01.02 HLA class-I and class-II restricted neoantigen loads predict overall survival in breast cancer
Background Tumors acquire numerous mutations during development and progression. These mutations give rise to neoantigens that can be recognized by T cells and generate antibodies. Tumor mutational burden (TMB) is correlated with, and has often been used as a surrogate of, neoantigen load, although that relationship is different depending on cancer types. Recent studies reported correlations between higher TMB and better overall survival after immune checkpoint blockade therapies in bladder, colorectal, head and neck, and lung cancers but not in breast cancer. On the other hand, the relationship between neoantigen load and survival has been controversial in literature. Higher neoantigen load has been linked to better overall survival in ovarian cancer and melanoma, but worse survival in multiple myeloma. Recently, no clear associations were found between neoantigen load and survival in 33 cancer types although only class-I restricted neoantigens were included. Materials and Methods We developed a bioinformatics workflow, REAL-neo, for identification, quality control (QC), and prioritization of both class-I and class-II human leukocyte antigen (HLA) bound neoantigens that arise from tumor somatic single nucleotide mutations (SNM), small insertions and deletions (INDEL), and gene fusions. The correlations between TMB and neoantigen load per sample were calculated using Pearson Correlation Coefficient. TMB and neoantigen load comparisons between various groups were performed using Student’s t-test. The survival analyses were performed using the Cox proportional hazards models while correcting for covariates. Results We applied REAL-neo to 835 primary breast tumors in the Cancer Genome Atlas (TCGA) and performed comprehensive profiling and characterization of the predicted neoantigens. SNMs contributed to only 6.25% of the total neoantigens (# of class-I vs. class-II neoantigens = 1: 3.5); INDELs accounted for 57.17% of the total (class-I : class-II= 1:2), and gene fusions were responsible for 36.58% of the total (class-I : class-II = 1:2.2). TMB were positively correlated with total and each sub-categories of neoantigen load (class I: SNM: r = 0.59, p < 2.2E-16; INDEL: r = 0.28, p < 2.2E-16; gene fusion: r = 0.26, p = 2.01E-11; class II: SNM: r = 0.47, p < 2.2E-16; INDEL: r = 0.16, p = 1.7E-05; gene fusion: r = 0.31, p = 4.37E-13). The vast majority (99.75%) of the predicted neoantigens occurred in ≤1% of the cases and 83.76% were patient-specific found in one patient only. Tumors with somatic and germline functional mutations in BRCA1 or BRCA2 genes had higher TMB (p = 2.76E-06) and overall neoantigen load (p = 0.009). Lower HLA class-I and class-II restricted neoantigen loads from SNM and INDEL were found to predict worse overall survival independent of TMB, breast cancer subtypes, tumor infiltrating lymphocyte (TIL) levels, tumor stage, and age at diagnosis (class-I: HR = 1.81, p = 0.04; class-II: HR = 1.89, p = 0.042). Conclusions Our study highlighted the importance of accurate and comprehensive neoantigen profiling and QC, and is the first to report the predictive value of neoantigen load for overall survival in breast cancer. This work was support by the State of Florida Cancer Center Grant, the bioinformatics program of Mayo Clinic Center for Individualized Medicine, and the Mayo Clinic inter-SPORE development grant. Disclosure Information Y.W. Asmann: None. Y. Ren: None. D.P. Wickland: None. V. Sarangi: None. S. Tian: None. J.M. Carter: None. A.S. Mansfield: None. M.S. Block: None. M.E. Sherman: None. K.L. Knutson: None. Y. Lin: None.
- 1 October 2020
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 8 (Suppl 2) , A8
Open AccessP01.02 HLA class-I and class-II restricted neoantigen loads predict overall survival in breast cancer
Background Tumors acquire numerous mutations during development and progression. These mutations give rise to neoantigens that can be recognized by T cells and generate antibodies. Tumor mutational burden (TMB) is correlated with, and has often been used as a surrogate of, neoantigen load, although that relationship is different depending on cancer types. Recent studies reported correlations between higher TMB and better overall survival after immune checkpoint blockade therapies in bladder, colorectal, head and neck, and lung cancers but not in breast cancer. On the other hand, the relationship between neoantigen load and survival has been controversial in literature. Higher neoantigen load has been linked to better overall survival in ovarian cancer and melanoma, but worse survival in multiple myeloma. Recently, no clear associations were found between neoantigen load and survival in 33 cancer types although only class-I restricted neoantigens were included. Materials and Methods We developed a bioinformatics workflow, REAL-neo, for identification, quality control (QC), and prioritization of both class-I and class-II human leukocyte antigen (HLA) bound neoantigens that arise from tumor somatic single nucleotide mutations (SNM), small insertions and deletions (INDEL), and gene fusions. The correlations between TMB and neoantigen load per sample were calculated using Pearson Correlation Coefficient. TMB and neoantigen load comparisons between various groups were performed using Student’s t-test. The survival analyses were performed using the Cox proportional hazards models while correcting for covariates. Results We applied REAL-neo to 835 primary breast tumors in the Cancer Genome Atlas (TCGA) and performed comprehensive profiling and characterization of the predicted neoantigens. SNMs contributed to only 6.25% of the total neoantigens (# of class-I vs. class-II neoantigens = 1: 3.5); INDELs accounted for 57.17% of the total (class-I : class-II= 1:2), and gene fusions were responsible for 36.58% of the total (class-I : class-II = 1:2.2). TMB were positively correlated with total and each sub-categories of neoantigen load (class I: SNM: r = 0.59, p < 2.2E-16; INDEL: r = 0.28, p < 2.2E-16; gene fusion: r = 0.26, p = 2.01E-11; class II: SNM: r = 0.47, p < 2.2E-16; INDEL: r = 0.16, p = 1.7E-05; gene fusion: r = 0.31, p = 4.37E-13). The vast majority (99.75%) of the predicted neoantigens occurred in ≤1% of the cases and 83.76% were patient-specific found in one patient only. Tumors with somatic and germline functional mutations in BRCA1 or BRCA2 genes had higher TMB (p = 2.76E-06) and overall neoantigen load (p = 0.009). Lower HLA class-I and class-II restricted neoantigen loads from SNM and INDEL were found to predict worse overall survival independent of TMB, breast cancer subtypes, tumor infiltrating lymphocyte (TIL) levels, tumor stage, and age at diagnosis (class-I: HR = 1.81, p = 0.04; class-II: HR = 1.89, p = 0.042). Conclusions Our study highlighted the importance of accurate and comprehensive neoantigen profiling and QC, and is the first to report the predictive value of neoantigen load for overall survival in breast cancer. This work was support by the State of Florida Cancer Center Grant, the bioinformatics program of Mayo Clinic Center for Individualized Medicine, and the Mayo Clinic inter-SPORE development grant. Disclosure Information Y.W. Asmann: None. Y. Ren: None. D.P. Wickland: None. V. Sarangi: None. S. Tian: None. J.M. Carter: None. A.S. Mansfield: None. M.S. Block: None. M.E. Sherman: None. K.L. Knutson: None. Y. Lin: None.